Sophie Testa to Male
This is a "connection" page, showing publications Sophie Testa has written about Male.
Connection Strength
0.085
-
Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study. Intern Emerg Med. 2020 Nov; 15(8):1425-1433.
Score: 0.012
-
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020 06; 18(6):1320-1323.
Score: 0.012
-
Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. Thromb Res. 2019 Mar; 175:61-67.
Score: 0.011
-
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med. 2018 Oct; 13(7):1051-1058.
Score: 0.010
-
Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia. Am J Dermatopathol. 2021 May 01; 43(5):342-348.
Score: 0.003
-
Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. Int J Infect Dis. 2021 Mar; 104:433-440.
Score: 0.003
-
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thromb Res. 2021 01; 197:20-23.
Score: 0.003
-
Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. Eur J Intern Med. 2019 Nov; 69:64-70.
Score: 0.003
-
Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. Thromb Res. 2019 Nov; 183:28-32.
Score: 0.003
-
The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study. Intern Emerg Med. 2019 11; 14(8):1307-1315.
Score: 0.003
-
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. Int J Cardiol. 2018 Sep 15; 267:68-73.
Score: 0.003
-
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 09 27; 132(13):1365-1371.
Score: 0.003
-
Galectin-3 and outcomes after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. Biomark Med. 2018 Jan; 12(1):21-26.
Score: 0.003
-
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma. Cardiovasc Ther. 2018 Feb; 36(1).
Score: 0.003
-
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med. 2017 Dec; 12(8):1109-1119.
Score: 0.002
-
Gastrointestinal bleeding during Direct Oral AntiCoagulants-anticoagulant therapy. Is there nothing so bad that is not good for something? Eur J Intern Med. 2017 04; 39:e25-e26.
Score: 0.002
-
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. Am J Cardiol. 2017 Apr 01; 119(7):1012-1016.
Score: 0.002
-
Intracranial hemorrhage recurrence on vitamin K antagonist: severity of the first episode and HASBLED score fail to identify high-risk patients from the CHIRONE study. Blood Coagul Fibrinolysis. 2017 Jan; 28(1):62-65.
Score: 0.002
-
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine (Baltimore). 2016 Dec; 95(52):e5451.
Score: 0.002